SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MulhollandDrive who wrote (633)9/1/1997 2:34:00 PM
From: Henry Niman   of 2173
 
BAP, The first sentence of each post included retinoid or retinoid receptors. These are non-polypeptide hormones or non-polypeptide hormone receptors (which I hope that all readers now understand). Although they will impact the diabetes market (actually Rezulin is already having a significant impact, just read the diabetes news groups or listservs) in ways that I have described previously, the non-polypeptide hormones will be related to LGND (Targretin) or WLA (Rezulin) or other companies such as SBH or Takeda which have 2nd generation TZDs (non-polypeptide hormones such as Rezulin) in advanced clinical trials. AMLN makes polypeptide hormones such as Pramlintide.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News